Hypertrophic Scar Clinical Trial
Official title:
Multicenter, Double Blind, Randomized, Controlled Clinical Investigation to Evaluate the Performance of Autocross-linked Hyaluronic Acid for the Treatment of Hypertrophic Scars
The study includes two study groups, one involves treatment with auto-cross-linked Hyaluronic acid by intralesional and hypodermic injection, repeated after two weeks (T14), while the control arm provides an equal treatment but with isotonic saline solution. Enrolled patients will be randomized into 2 groups with an allocation of 2:1 in study treatment arm and control arm respectively. They will be evaluated using the POSAS scale before the treatment and re-evaluated at 30, 90 and 180 days after treatment. The scar evaluation will be completed by an ultrasound assessment at time 0 (T0), 30 (T30), T90 and T180 and the DLQI (Dermatology Life Quality Index) to be assessed at time 0 (T0), 30 (T30), 90 (T90) and 180 (T180). In subjects that will consent, a small surgical biopsy for an explorative evaluation of the scar tissue will be performed before (T0) and after treatment (T30) for a histological assessment.
Status | Recruiting |
Enrollment | 78 |
Est. completion date | December 31, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Signed written informed consent - Male or female subjects aged = 18 and = 85 years - Subjects with hypertrophic scars caused by trauma, burn or iatrogenic injury with or without involvement of the mobile joints - Scar > 2 to < 25 cm2 of surface - Scar not previously treated with corticosteroids, laser or other invasive treatments - Scar present for at least 12 months - Scar located in all areas of the body with the exception of the face and neck - Fitzpatrick skin score of I-VI - Subjects willing to comply with all the steps of treatment and follow-up visits - Subjects willing to refrain from any cosmetic intervention in the area to be treated during the clinical investigation - Female of child-bearing potential (i.e. not in menopausal status from at least one year or permanently sterilized) must have a negative urine pregnancy test prior the first treatment Exclusion Criteria: Subjects with type I and type II diabetes mellitus - Subjects with oncological diseases in progress or in remission - Subjects receiving immunosuppressive drugs and corticosteroids, anticoagulants, antiplatelet agents - Subjects with autoimmune diseases including connectivitis - Subjects with congenital or acquired immunodeficiencies (including metabolic ones) - Subjects with known allergy or hypersensitivity to hyaluronic acid or its derivatives - Participation in clinical trials/investigations in the last 30 days - Pregnant or breastfeeding women - If female and of child-bearing potential, subject not using a highly effective method of birth control and not willing to use it during the participation to the clinical investigation - Subjects not willing to avoid tanning during the clinical investigation - Subjects with inflammations of the skin, including rosacea - Subject with skin infection in the area to be treated - Subjects having a high probability of non-compliance with the study procedures according to Investigator's judgement |
Country | Name | City | State |
---|---|---|---|
Italy | AOU Ospedali Riuniti- SOD Chirurgia ricostruttiva e chirurgia della mano | Ancona | |
Italy | U.O. Centro Grandi Ustionati Ospedale Bufalini di Cesena - AUSL | Cesena | |
Italy | U.O.C. Chirurgia Plastica e Centro Ustioni Azienda Ospedaliero-Universitaria di Parma | Parma | |
Italy | U.O.C. Centro Ustioni Azienda Ospedaliero-Universitaria Pisana | Pisa |
Lead Sponsor | Collaborator |
---|---|
Fidia Farmaceutici s.p.a. |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline to Day 90 in POSAS total score for Observer | The performance of two injections of IAL-SYSTEM ACP in improving the quality of the scar after 90 days from the first treatment in patients with hypertrophic scars will be evaluated by the mean change from baseline to Day 90 in POSAS total score for Observer. | 90 days after treatment | |
Secondary | To evaluate the performance of IAL-SYSTEM ACP in improving the quality of the scar | Change from baseline to post-baseline visits (T30, T90 and T180) in total POSAS scores (sum total of Patient and Observer scores), and POSAS total score for Patient and Observer | after 30 and 180 days from the first treatment | |
Secondary | To assess the changing in the Quality of life after 30, 90 and 180 days from the first treatment with the Dermatology Life Quality Index (DLQI) | Change from baseline to post-baseline visits (T30, T90 and T180) in DLQI score (dermatology quality of life Index) | after 30, 90 and 180 days from the first treatment | |
Secondary | To assess the changing in the dermal volume after 30, 90 and 180 days from the first treatment | Change from baseline to post-baseline visits (T30, T90 and T180) in dermal volume measured by ultrasound | after 30, 90 and 180 days | |
Secondary | Safety of the treatment. Number of patients with treatment related adverse events | Safety evaluation examining the local and systemic adverse effects as consequence of the treatment and any other adverse event occurred during the study. | throug clinical investigation completion, an average one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03376620 -
Role of Topical Putrescine (Fibrostat) for Prevention of Hypertrophic Scars in Mammoplasty Patients
|
Phase 3 | |
Terminated |
NCT03935594 -
Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars
|
Phase 2 | |
Recruiting |
NCT03561376 -
Zinc Oxide Versus Petrolatum Following Skin Surgery
|
Early Phase 1 | |
Recruiting |
NCT06033430 -
Effectiveness of Dry Needling in Linear Scar Tissue
|
N/A | |
Recruiting |
NCT03631368 -
Treatment of Hypertrophic Scars With Intradermal Botox
|
Phase 2 | |
Completed |
NCT03630198 -
Pain Outcomes Following Intralesional Corticosteroid Injections
|
Phase 4 | |
Recruiting |
NCT02168634 -
The Use of Botulinum Toxin in the Treatment of Itching From Hypertrophic Scar -- A Randomised Controlled Trial
|
N/A | |
Completed |
NCT02030275 -
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults
|
Phase 2 | |
Recruiting |
NCT04506255 -
Silicone Taping for the Improvement of Abdominal Donor Site Scars
|
N/A | |
Not yet recruiting |
NCT04593706 -
Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars)
|
N/A | |
Completed |
NCT04643223 -
Effect of Elastic Bandage With Tension on the Inflammatory Response of Hypertrophic Scars
|
N/A | |
Completed |
NCT03986346 -
The Vascularity Changes of Scars With Laser Therapy
|
N/A | |
Completed |
NCT04619589 -
Characterization of Dyschromic Hypertrophic Scar
|
||
Completed |
NCT06347081 -
Effect of Nd-YAG Laser on Hypertrophic Scar
|
N/A | |
Completed |
NCT05412745 -
Class I Medical Device on Post-surgical Scars
|
N/A | |
Terminated |
NCT03403621 -
Hypertrophic Scar Prevention by Novel Topical Gel Application
|
Phase 1/Phase 2 | |
Completed |
NCT00754247 -
A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars
|
Phase 4 | |
Recruiting |
NCT03692273 -
Randomized Control Trial of CO2 Laser to Treat Hypertrophic Burn Scar
|
N/A | |
Completed |
NCT03795116 -
Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention
|
Phase 2 | |
Not yet recruiting |
NCT03850119 -
Nanofat on Wound Healing and Scar Formation
|
N/A |